Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Closes Final Round of Financing for Completion of New Advanced Development and Manufacturing Facility

Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.

The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.

Read More

Nanotherapeutics Receives Expanded 510(K) Marketing Clearance from the FDA for NanoFUSE® DBM

Nanotherapeutics, Inc., a company focused on advanced development and manufacturing, today announced that the Company’s proprietary bone void filler product, NanoFUSE® DBM (demineralized bone matrix), has received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use in spinal fusion surgery. Specifically, NanoFUSE® DBM has been cleared for use with autograft (transplanted bone from a patient’s own body) as a bone graft extender in the posterolateral spine.

Read More

Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics

Baxter International Inc. (BAX) today announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed.

The Vero cell platform is an advanced, cell-based technology for vaccines production. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus.

In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer Inc.

Full Article

Manufacturing Issues Crucial to Combating Ebola

A key challenge in testing and developing new therapies to combat the Ebola virus involves producing sufficient quantities of candidate treatments to conduct clinical trials and then to facilitate commercial scale-up for any product demonstrating effectiveness. Clinical trials are being launched for several promising Ebola therapies and vaccines, and successful results will require massive efforts to produce the millions of doses needed to treat and prevent further spread of the virus. 

Read More

Pharmathene and Nanotherapeutics Form Strategic Alliance To Advance Biodefense Programs

PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.

Full Article

Ohio Doctor Leads Cervical Cancer Study of Promising Drug

An Akron physician is leading a national clinical trial with the goal of improving survival rates for cervical cancer patients worldwide.

Dr. Charles Kunos, medical director of radiation oncology at Summa Akron City Hospital, is heading a National Cancer Institute study to determine whether a compound called Triapine results in a better chance for a cure when combined with the traditional treatments of chemotherapy and radiation.

Full Article

Nanotherapeutics Opens New Office in Frederick, MD

Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on development and manufacturing, announced today the opening of a new, 4,800 square foot office, located at 8490 Progress Drive, Suite 450, Frederick, MD. The office, established to better support the Company’s U.S. Government contracts, is within RiversideFive, a four story, Class A office building, developed and managed by Matan Companies. With headquarters in Alachua, FL and a clinical team located in Durham, NC, close to many of the most prominent contract research organizations, Nanotherapeutics now has three, strategically located offices.

Full Article

Nanotherapeutics Secures $30 Million Loan Facility from Hercules Technology Growth Capital - June 2014

Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $30 million loan facility from Hercules Technology Growth Capital, Inc. The funds from the loan facility will support the Company’s efforts to expand its manufacturing infrastructure.

Full Article

Nanotherapeutics, Inc. Concludes Type C Meeting with the U.S. Food and Drug Administration - November 2013

Nanotherapeutics, Inc. announced today that on November 20, 2013, the Company held a Type C meeting with the U.S. Food and Drug Administration (“FDA”), providing an opportunity for the FDA to review and provide feedback on Nanotherapeutics’ plans for its Advanced Development and Manufacturing (NANO-ADM) Center facility to be located in Copeland Park, Alachua, FL.

Full Article

Nanotherapeutics Celebrates Groundbreaking of its Advanced Development and Manufacturing Center (NANO-ADM) in Copeland Park, Alachua, FL - October 2013 

Nanotherapeutics, Inc. today announced that a groundbreaking ceremony for its Advanced Development and Manufacturing Center (NANO-ADM) in Copeland Park, Alachua, FL, will be held this morning at 9:00am ET. The event will be hosted by Tim Giuliani, President of the Gainesville Area Chamber of Commerce.

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.